Medicross Healthcare Group (Pty) Ltd and Prime Cure Holdings (Pty) Ltd v The Competition Commission

Medicross Healthcare Group (Pty) Ltd sought to acquire the entire issued share capital of Prime Cure Holdings (Pty) Ltd for R85 million. The transaction was notified as a large merger under section 13A of the Competition Act 89 of 1998. The Competition Commission investigated and recommended that the merger be prohibited, finding that it would substantially lessen competition in the national market for managed healthcare services with a national provider network. The Competition Tribunal accepted this recommendation and prohibited the merger, primarily on the basis of horizontal effects and high barriers to entry. Medicross and Prime Cure appealed to the Competition Appeal Court.

The appeal was upheld. The Tribunal’s decision prohibiting the merger was set aside and replaced with an order approving the merger unconditionally.

This case is significant for clarifying the proper interpretation and application of section 12A of the Competition Act. It firmly establishes the two-stage merger analysis and confirms that public interest considerations may not influence the initial competition assessment. The judgment reinforces the limits of the Tribunal’s discretion and the appellate court’s role in correcting misapplications of statutory tests.